US FDA Reviews IBS-C Candidates Both New (Tenapanor) And Old (Tegaserod)

Ardelyx touts tenapanor's novel mechanism, favorable safety profile; advisory committee announcement reveals US Worldmeds’ bid to revive Novartis’ withdrawn Zelnorm.

Ardelyx Inc.’s tenapanor is on track for an FDA approval decision in irritable bowel syndrome with constipation (IBS-C) by mid-September 2019, but the company is still seeking a US partner.

“Tenapanor would be the first medication available that works by reducing sodium uptake from the gut,” Ardelyx emphasized in its...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet